Drug Database
Back to search

France· FR:65314130

APREPITANT EVOLUGEN 125 mg, gélule et APREPITANT EVOLUGEN 80 mg, gélule

A aprepitant product containing aprépitant, registered in France by EVOLUPHARM, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC A04AD12

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedAPREPITANT EVOLUGEN 125 mg, gélule et…ATCA04AD12REGISTER NO.FR:65314130PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about aprépitantAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aprepitant is registered in 17 of 19 countries.

Countries holding a registration under ATC A04AD12 (aprepitant), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search aprepitant products by name

Aprepitant · ATC A04AD12

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of aprepitant costs, country by country.

Normalised to the WHO defined daily dose (165 mg), the median price runs from $0.40 in Finland to $157.48 in United States — a ×394 gap.

  • France: $33.15 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Aprepitant · price per daily dose (165 mg)

USD · FX 28 Sept 2026

  • US United States$157.48 (acquisition cost)
  • CH Switzerland$73.26
  • FR France$33.15
  • FI Finland$0.40
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
APRÉPITANT
Manufacturer
EVOLUPHARM
Country
France (FR)
ATC code
A04AD12
ATC class
Aprepitant
Defined daily dose
165 mg, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930168950
    plaquette(s) aluminium OPA : polyamide orienté PVC de 1 gélule de 125 mg rose et blanche - plaquette(s) aluminium OPA : polyamide orienté PVC de 2 gélules de 80 mg blanches
    EUR 22.06

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

583 interactions on record for aprepitant.

Graded by severity as the source publishes them — 73 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check aprepitant against other medicinesHow interaction checks work

Aprepitant · interactions on record

583 records

  • 73 severe
  • 380 moderate
  • 25 minor
  • 104 info

Most severe, free to view

  • CisaprideA03FA02severe
  • NaloxegolA06AH03severe
  • EliglustatA16AX10severe
  • LonafarnibA16AX20severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aprepitant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aprepitant products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Aprepitant Accord, Aprepitant Ratiopharm
  • Belgium · Aprepitant Sandoz, Aprepitant Teva
  • Cyprus · Atanto, Endrem
  • Czechia · Aprepitant Accord, Aprepitant Sandoz
  • Germany · Aprepilor, Aprepitant Al
  • Denmark · Aprepitant "medical Valley", Aprepitant Medical Valley
  • Estonia · Aprepitant Sandoz
  • Spain · Aprepitant Accord, Aprepitant Qilu
  • Finland · Aprepitant Stada
  • United Kingdom (Northern Ireland) · Aprepitant, Aprepitant Accord
  • Greece · Aprepitant Win Medica, Atanto
  • Croatia · Aprepitant Alpha-Medical, Aprepitant Sandoz
  • Hungary · Aprepitant Pharmacenter, Aprepitant Q Pharma
  • Ireland · Aprepitant Accord
  • Iceland · Aprepitant Medical Valley, Aprepitant Stada
  • Italy · Aprepitant Accord, Aprepitant Teva
  • Liechtenstein · Emend
  • Lithuania · Aprepitant Sandoz
  • Latvia · Aprepitant Sandoz
  • Netherlands · Aprepitant Accord, Aprepitant Aurobind
  • Norway · Emend
  • Poland · Aprepitant Accord, Aprepitant Sandoz
  • Portugal · Aprepitant Generis
  • Sweden · Aprepitant Medical Valley, Aprepitant Stada
  • Slovenia · Aprepitant Teva
  • Slovakia · Aprepitant, Aprepitant Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e449549a-4de8-4ed2-8e7e-94084a7f8209
GET /v1/drugs/e449549a-4de8-4ed2-8e7e-94084a7f8209?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65314130",
  "date_amm": "2019-01-23",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "APRÉPITANT",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "gélule et  gélule",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about aprepitant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console